Minimal residual disease response with venetoclax monotherapy in relapsed/refractory CLL patients: VENICE I, phase 3b exploratory analysis
dc.contributor.author | Aktan, Melih | |
dc.contributor.author | Breuleux, Madlaina | |
dc.contributor.author | Enggaard, Lisbeth | |
dc.contributor.author | DEMİRKAN, FATİH | |
dc.contributor.author | ARSLAN, ÖNDER | |
dc.contributor.author | Turgut, Mehmet | |
dc.contributor.author | Fort, Stan | |
dc.contributor.author | Forconi, Francesco | |
dc.contributor.author | Masud, Abdullah | |
dc.contributor.author | Chyla, Brenda | |
dc.contributor.author | Kater, Arnon | |
dc.contributor.author | Panagiotis, Panayiotidis | |
dc.contributor.author | Thornton, Patrick | |
dc.contributor.author | Tempescul, Adrian | |
dc.contributor.author | Skarbnik, Alan | |
dc.contributor.author | Rossi, Davide | |
dc.contributor.author | Montillo, Marco | |
dc.contributor.author | Leber, Brian | |
dc.contributor.author | Karlsson, Karin | |
dc.contributor.author | Herishanu, Yair | |
dc.contributor.author | Gonzalez Diaz, Marcos | |
dc.contributor.author | Ferhanoglu, Burhan | |
dc.date.accessioned | 2021-03-05T07:19:56Z | |
dc.date.available | 2021-03-05T07:19:56Z | |
dc.identifier.citation | Kater A., Panagiotis P., Aktan M., ARSLAN Ö., DEMİRKAN F., Enggaard L., Ferhanoglu B., Gonzalez Diaz M., Herishanu Y., Karlsson K., et al., "Minimal residual disease response with venetoclax monotherapy in relapsed/refractory CLL patients: VENICE I, phase 3b exploratory analysis", LEUKEMIA & LYMPHOMA, cilt.61, ss.113-115, 2020 | |
dc.identifier.issn | 1042-8194 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_933f7dc9-20f0-4bc0-9104-c32bb362c464 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/99258 | |
dc.language.iso | eng | |
dc.subject | HEMATOLOJİ | |
dc.subject | Hematoloji | |
dc.subject | İç Hastalıkları | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Onkoloji | |
dc.title | Minimal residual disease response with venetoclax monotherapy in relapsed/refractory CLL patients: VENICE I, phase 3b exploratory analysis | |
dc.type | Makale | |
dc.relation.journal | LEUKEMIA & LYMPHOMA | |
dc.contributor.department | AbbVie , , | |
dc.identifier.volume | 61 | |
dc.identifier.startpage | 113 | |
dc.identifier.endpage | 115 | |
dc.contributor.firstauthorID | 2279232 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Makale [92796]